University College London - Queen Square Institute of Neurology
Identifying genetic modifiers of disease in MSA to facilitate clinical intervention
2022
UNITED KINGDOM
Supported project of Henry Houlden : Multiple system atrophy (MSA) is a rare neuropathologically defined disease characterised by the formation of alpha-synuclein positive glial-cytoplasmic-inclusions. The overall goal of this project is to comprehensively study the genetic risks, determinants of survival and the alpha-synuclein (SNCA) region in detail. This project aims to change the focus from symptomatic care in MSA to a molecular and genotype orientation, promoting the importance of prognosis and prediction.